• Novo Nordisk announced real-world study results linking Wegovy to improved liver enzymes, weight and blood sugar in adults with MASH.
• Results from PLATINUM-Truveta and RHODIUM-2 were presented at the American Association for the Study of Liver Diseases meeting in Denver in 2026.
• PLATINUM-Truveta linked Wegovy to greater reductions in weight, blood sugar and a liver enzyme than resmetirom at six months.
• RHODIUM-2 found greater improvements in liver enzymes, weight and blood sugar over one year versus patients who did not initiate semaglutide.
• Both studies were retrospective and observational, meaning the findings establish associations rather than prove treatment effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.